Update on immune‐based therapy strategies targeting cancer stem cells
暂无分享,去创建一个
Marzieh Ebrahimi | Mahsa Ghasemzad | Arefeh Saeedian | Niloufar Mohammadkhani | Amirhossein Izadpanah | Mina Masoudnia | Hamid Mehdizadeh | Mansour Poorebrahim
[1] A. Samadani,et al. Immune checkpoint inhibitors promising role in cancer therapy: clinical evidence and immune-related adverse events , 2023, Medical Oncology.
[2] K. Mortezaee,et al. Advances in dendritic cell vaccination therapy of cancer. , 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[3] F. Tajik,et al. Efficacy of Whole Cancer Stem Cell-Based Vaccines: A Systematic Review of Preclinical and Clinical Studies. , 2022, Stem cells.
[4] A. Safa. Drug and apoptosis resistance in cancer stem cells: a puzzle with many pieces , 2022, Cancer drug resistance.
[5] Yue Zheng,et al. Lung Cancer Stem Cell Markers as Therapeutic Targets: An Update on Signaling Pathways and Therapies , 2022, Frontiers in Oncology.
[6] G. Robertson,et al. Drug-tolerant persister cells in cancer therapy resistance. , 2022, Cancer research.
[7] Guangjun Nie,et al. Modulation of Tumor Vasculature Network: Key Strategies , 2022, Small Structures.
[8] Xueqing Yu,et al. Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors , 2021, International journal of molecular sciences.
[9] G. McFadden,et al. Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy , 2021, Cancers.
[10] Mansour Poorebrahim,et al. CAR-T Cells in Brain Tumors and Autoimmune Diseases – from Basics to the Clinic , 2021, Frontiers in Clinical Drug Research - CNS and Neurological Disorders.
[11] T. Lee,et al. Cancer Stem Cells: Emerging Key Players in Immune Evasion of Cancers , 2021, Frontiers in Cell and Developmental Biology.
[12] R. Greil,et al. CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues. , 2021, Blood.
[13] Wei Wei,et al. CAR-macrophage: A new immunotherapy candidate against solid tumors. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[14] Dean Anthony Lee,et al. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future , 2021, Stem cell research & therapy.
[15] G. Shiota,et al. Immune evasion by cancer stem cells , 2021, Regenerative therapy.
[16] Mansour Poorebrahim,et al. TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential , 2021, Cancer Gene Therapy.
[17] M. Aglietta,et al. Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective , 2021, Cells.
[18] Y. Xuan,et al. Simultaneously target of normal and stem cells-like gastric cancer cells via cisplatin and anti-CD133 CAR-T combination therapy , 2021, Cancer Immunology, Immunotherapy.
[19] M. Borad,et al. Evolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice. , 2021, JCO precision oncology.
[20] Yuhong Shang,et al. Chimeric Antigen receptor-T (CAR-T) cells targeting Epithelial cell adhesion molecule (EpCAM) can inhibit tumor growth in ovarian cancer mouse model , 2020, The Journal of veterinary medical science.
[21] M. Caligiuri,et al. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy , 2020, Journal of Hematology & Oncology.
[22] S. Wongkham,et al. Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells. , 2020, International immunopharmacology.
[23] Qiaojun He,et al. Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy , 2020, Drug design, development and therapy.
[24] F. Farassati,et al. Targeting Cancer Stem Cells by Oncolytic Viruses and Nano-Mediated Delivery , 2020, OncoTargets and therapy.
[25] T. Yevsa,et al. Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies , 2020, Frontiers in Immunology.
[26] Hongmei Zhou,et al. Radiotherapy targeting cancer stem cells “awakens” them to induce tumour relapse and metastasis in oral cancer , 2020, International Journal of Oral Science.
[27] R. Kiessling,et al. Genetically modified immune cells targeting tumor antigens. , 2020, Pharmacology & therapeutics.
[28] Kazuhiro Takahashi,et al. Possibility of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using 211At-CXCR4 monoclonal antibody , 2020, Scientific Reports.
[29] C. Pérez-Plasencia,et al. Cancer Stem Cells and Its Role in Angiogenesis and Vasculogenic Mimicry in Gastrointestinal Cancers , 2020, Frontiers in Oncology.
[30] Martha E. Zeeman,et al. Human chimeric antigen receptor macrophages for cancer immunotherapy , 2020, Nature Biotechnology.
[31] Shibing Wang,et al. Recent advances in targeting cancer stem cells using oncolytic viruses , 2020, Biotechnology Letters.
[32] Marzieh Ebrahimi,et al. HSP70/IL-2 Treated NK Cells Effectively Cross the Blood Brain Barrier and Target Tumor Cells in a Rat Model of Induced Glioblastoma Multiforme (GBM) , 2020, International journal of molecular sciences.
[33] T. Chieochansin,et al. Breast cancer stem cell RNA-pulsed dendritic cells enhance tumor cell killing by effector T cells , 2020, Oncology letters.
[34] S. Hou,et al. Arf1-mediated lipid metabolism sustains cancer cells and its ablation induces anti-tumor immune responses in mice , 2020, Nature Communications.
[35] F. Mansour,et al. PD-L1 is overexpressed on breast cancer stem cells through notch3/mTOR axis , 2020, Oncoimmunology.
[36] Pingping Shen,et al. Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial , 2020, Oncoimmunology.
[37] F. Gage,et al. Zika Virus Targets Glioblastoma Stem Cells through a SOX2-Integrin αvβ5 Axis. , 2019, Cell stem cell.
[38] A. Alam,et al. Wnt Signaling and Its Significance Within the Tumor Microenvironment: Novel Therapeutic Insights , 2019, Front. Immunol..
[39] M. Fiore,et al. Cancer stem cells-driven tumor growth and immune escape: the Janus face of neurotrophins , 2019, Aging.
[40] M. Salem,et al. Dual-targeted therapeutic strategy combining CSC–DC-based vaccine and cisplatin overcomes chemo-resistance in experimental mice model , 2019, Clinical and Translational Oncology.
[41] L. Quintanilla‐Martinez,et al. GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells , 2019, Oncoimmunology.
[42] A. Tong,et al. Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances , 2019, Molecular therapy oncolytics.
[43] C. Jordan. Can we selectively target AML stem cells? , 2019, Best practice & research. Clinical haematology.
[44] Sang-Woon Choi,et al. Natural Killer Cell Therapy: A New Treatment Paradigm for Solid Tumors , 2019, Cancers.
[45] P. Wen,et al. Construction of chimeric antigen receptor‑modified T cells targeting EpCAM and assessment of their anti‑tumor effect on cancer cells. , 2019, Molecular medicine reports.
[46] T. Regad,et al. Cancer Stem Cells and Targeting Strategies , 2019, Cells.
[47] A. Bullock,et al. A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer , 2019, Cancer medicine.
[48] K. Sugamura,et al. Humanized anti-CD271 monoclonal antibody exerts an anti-tumor effect by depleting cancer stem cells. , 2019, Cancer letters.
[49] A. Safa. Resistance to drugs and cell death in cancer stem cells (CSCs) , 2019, Journal of translational science.
[50] Weilei Hu,et al. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities , 2019, Front. Immunol..
[51] M. Kawada,et al. Anti-CD133 Monoclonal Antibody CMab-43 Exerts Antitumor Activity in a Mouse Xenograft Model of Colon Cancer. , 2019, Monoclonal antibodies in immunodiagnosis and immunotherapy.
[52] L. Kandalaft,et al. Personalized Dendritic Cell Vaccines—Recent Breakthroughs and Encouraging Clinical Results , 2019, Front. Immunol..
[53] M. Todaro,et al. Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway , 2019, Cancer Immunology Research.
[54] Yu‐quan Wei,et al. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer. , 2019, Human gene therapy.
[55] Alexandra G. Smith,et al. Autophagy, cancer stem cells and drug resistance , 2019, The Journal of pathology.
[56] A. Esmaeilzadeh,et al. Therapeutics strategies against cancer stem cell in breast cancer. , 2019, The international journal of biochemistry & cell biology.
[57] A. Schambach,et al. Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer , 2019, International journal of molecular sciences.
[58] Yongchang Wei,et al. Therapeutic Potential of Natural Killer Cells in Gastric Cancer , 2019, Front. Immunol..
[59] G. Vassalli. Aldehyde Dehydrogenases: Not Just Markers, but Functional Regulators of Stem Cells , 2019, Stem cells international.
[60] H. Calderon,et al. Engineering and Design of Chimeric Antigen Receptors , 2018, Molecular therapy. Methods & clinical development.
[61] A. Avan,et al. Therapeutic potency of oncolytic virotherapy–induced cancer stem cells targeting in brain tumors, current status, and perspectives , 2018, Journal of cellular biochemistry.
[62] Junnian Zheng,et al. Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models , 2018, Journal of immunology research.
[63] Bingyu Zhang,et al. Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model , 2018, Journal of immunotherapy.
[64] R. Rahbarghazi,et al. Cancer stem cells‐emanated therapy resistance: Implications for liposomal drug delivery systems , 2018, Journal of controlled release : official journal of the Controlled Release Society.
[65] Bingyu Zhang,et al. Potential function of CTLA-4 in the tumourigenic capacity of melanoma stem cells. , 2018, Oncology letters.
[66] Jian Hu,et al. Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial , 2018, Cancer Immunology, Immunotherapy.
[67] Agata Olejniczak,et al. Cancer stem cells as targets for DC-based immunotherapy of colorectal cancer , 2018, Scientific Reports.
[68] J. Nör,et al. Expression of Cancer Stem Cell Biomarkers in Human Head and Neck Carcinomas: a Systematic Review , 2018, Stem Cell Reviews and Reports.
[69] Emanuela M. Ghia,et al. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. , 2018, Cell stem cell.
[70] Zhiqiang Wu,et al. CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial , 2018, Oncoimmunology.
[71] Xingxu Huang,et al. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells. , 2018, Human gene therapy.
[72] B. J. Morrison,et al. Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells , 2018, BMC cancer.
[73] S. Chaurasiya,et al. Oncolytic Virotherapy versus Cancer Stem Cells: A Review of Approaches and Mechanisms , 2018, Cancers.
[74] Pavel Sumazin,et al. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma , 2018, Neuro-oncology.
[75] T. Kanaseki,et al. Cancer stem cells as targets for immunotherapy , 2018, Immunology.
[76] Ita Novita Sari,et al. Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment , 2018, Stem cells international.
[77] D. V. Von Hoff,et al. Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma , 2018, Clinical Cancer Research.
[78] M. Hidalgo,et al. Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC , 2018, Targeted Oncology.
[79] Bairong Shen,et al. Ginsenoside Rg3 targets cancer stem cells and tumor angiogenesis to inhibit colorectal cancer progression in vivo , 2017, International journal of oncology.
[80] S. Gerson,et al. New Opportunities and Challenges to Defeat Cancer Stem Cells. , 2017, Trends in cancer.
[81] J. Rosenfeld,et al. Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma , 2017, Molecular Cancer Therapeutics.
[82] Justin M. Richner,et al. Zika virus has oncolytic activity against glioblastoma stem cells , 2017, The Journal of experimental medicine.
[83] H. Clevers,et al. Cancer stem cells revisited , 2017, Nature Medicine.
[84] A. Schambach,et al. Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy. , 2017, Human gene therapy.
[85] Lifeng Peng,et al. Cancer stem cells in colorectal cancer: a review , 2017, Journal of Clinical Pathology.
[86] P. Agostinis,et al. Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape. , 2017, Trends in immunology.
[87] N. Cheung,et al. Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. , 2017, Cancer treatment reviews.
[88] Olfat Al-Harazi,et al. PD‐L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation , 2017, International journal of cancer.
[89] R. Wechsler-Reya,et al. Brain Tumor Stem Cells Remain in Play. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] C. Ryu,et al. Cancer stem cell surface markers on normal stem cells , 2017, BMB reports.
[91] Weiping Zou,et al. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy , 2017, Nature Reviews Immunology.
[92] Sung-Soo Yoon,et al. Novel phase 1a/1b dose-finding study design of CWP232291 (CWP291) in relapsed or refractory myeloma (MM). , 2017 .
[93] Jesus I. Luna,et al. Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy , 2017, Expert opinion on biological therapy.
[94] W. Seeger,et al. Pirfenidone exerts anti-fibrotic effects through Inhibition of GLI transcription factors , 2017, Pneumologie.
[95] Lin Sun,et al. Monoclonal antibodies targeting non-small cell lung cancer stem-like cells by multipotent cancer stem cell monoclonal antibody library. , 2017, International journal of oncology.
[96] C. Crane,et al. Genetically Engineered Macrophages: A Potential Platform for Cancer Immunotherapy. , 2017, Human gene therapy.
[97] F. Aberger,et al. Acute myeloid leukemia – strategies and challenges for targeting oncogenic Hedgehog/GLI signaling , 2017, Cell Communication and Signaling.
[98] J. Connolly,et al. Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis , 2017, Oncotarget.
[99] D. Benson,et al. Combination Therapy with Daratumumab and CAR-NK Targeting CS1 for Multiple Myeloma , 2016 .
[100] V. Orian-Rousseau,et al. CD44: More than a mere stem cell marker. , 2016, The international journal of biochemistry & cell biology.
[101] F. Mégraud,et al. Characterization of Biomarkers of Tumorigenic and Chemoresistant Cancer Stem Cells in Human Gastric Carcinoma , 2016, Clinical Cancer Research.
[102] E. Hurt,et al. Therapeutic Efficacy of Cancer Stem Cell Vaccines in the Adjuvant Setting. , 2016, Cancer research.
[103] W. Fan,et al. PKCε inhibits isolation and stemness of side population cells via the suppression of ABCB1 transporter and PI3K/Akt, MAPK/ERK signaling in renal cell carcinoma cell line 769P. , 2016, Cancer letters.
[104] Pedro E. M. Lopes,et al. The Small Molecule IMR-1 Inhibits the Notch Transcriptional Activation Complex to Suppress Tumorigenesis. , 2016, Cancer research.
[105] J. Miller,et al. Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells , 2016, Targeted Oncology.
[106] Marzieh Ebrahimi,et al. Dendritic cell based immunotherapy using tumor stem cells mediates potent antitumor immune responses. , 2016, Cancer letters.
[107] Xinyuan Liu,et al. GP73-regulated oncolytic adenoviruses possess potent killing effect on human liver cancer stem-like cells , 2016, Oncotarget.
[108] S. Yoo,et al. A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer , 2016, Oncotarget.
[109] Qin Liu,et al. Human cancer cells with stem cell-like phenotype exhibit enhanced sensitivity to the cytotoxicity of IL-2 and IL-15 activated natural killer cells. , 2016, Cellular immunology.
[110] Kaori Tanaka,et al. Aldehyde dehydrogenase 1A1 in stem cells and cancer , 2016, Oncotarget.
[111] R. Rosell,et al. Cancer stem cells and immunoresistance: clinical implications and solutions. , 2015, Translational lung cancer research.
[112] C. Diaconu,et al. Therapies targeting cancer stem cells: Current trends and future challenges. , 2015, World journal of stem cells.
[113] H. Saya,et al. Therapeutic strategies targeting cancer stem cells , 2015, Cancer science.
[114] T. Sayers,et al. NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype , 2015, The Journal of Immunology.
[115] A. Chang,et al. Promise of cancer stem cell vaccine , 2015, Human vaccines & immunotherapeutics.
[116] P. Munster,et al. Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours. , 2015, European journal of cancer.
[117] K. Kimata,et al. Key Roles of Hyaluronan and Its CD44 Receptor in the Stemness and Survival of Cancer Stem Cells , 2015, Front. Oncol..
[118] J. Iovanna,et al. Targeting CD44 as a novel therapeutic approach for treating pancreatic cancer recurrence , 2015, Oncoscience.
[119] J. Ajani,et al. Cancer stem cells: the promise and the potential. , 2015, Seminars in oncology.
[120] Z. Werb,et al. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? , 2015, Cell stem cell.
[121] A. Harris,et al. A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors , 2015, Clinical Cancer Research.
[122] P. Valent,et al. Cancer stem cells in basic science and in translational oncology: can we translate into clinical application? , 2015, Journal of Hematology & Oncology.
[123] Yu Yang,et al. Targeting lung cancer stem-like cells with TRAIL gene armed oncolytic adenovirus , 2015, Journal of cellular and molecular medicine.
[124] Yanhong Wu,et al. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM , 2015, BMC Immunology.
[125] A. Mackiewicz,et al. Immunotargeting of cancer stem cells , 2015, Contemporary oncology.
[126] O. Gires,et al. EpCAM and the biology of hepatic stem/progenitor cells , 2014, American journal of physiology. Gastrointestinal and liver physiology.
[127] M. Hettich,et al. Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57 , 2014, Oncotarget.
[128] W. Murphy,et al. Enhanced natural killer cell targeting of cancer stem cells using Cetuximab , 2014, Journal of Immunotherapy for Cancer.
[129] Yingge Zhang,et al. The effect of hyaluronic acid functionalized carbon nanotubes loaded with salinomycin on gastric cancer stem cells. , 2014, Biomaterials.
[130] C. Cordon-Cardo,et al. Targeting cancer stem cells to suppress acquired chemotherapy resistance , 2014, Oncogene.
[131] H. Fine,et al. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells , 2014, Journal of Immunotherapy for Cancer.
[132] Wenjun Guo. Concise Review: Breast Cancer Stem Cells: Regulatory Networks, Stem Cell Niches, and Disease Relevance , 2014, Stem cells translational medicine.
[133] D. Raha,et al. The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. , 2014, Cancer research.
[134] C. Naujokat. Monoclonal antibodies against human cancer stem cells. , 2014, Immunotherapy.
[135] J. Wischhusen,et al. Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1) , 2014, Cell Death and Disease.
[136] E. Nievergall,et al. Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells. , 2014, Blood.
[137] D. Hayes,et al. Hedgehog–GLI Signaling Inhibition Suppresses Tumor Growth in Squamous Lung Cancer , 2014, Clinical Cancer Research.
[138] Yan Gao,et al. Effects and Mechanisms of Anti-CD44 Monoclonal Antibody A3D8 on Proliferation and Apoptosis of Sphere-Forming Cells With Stemness From Human Ovarian Cancer , 2013, International Journal of Gynecologic Cancer.
[139] Ke Chen,et al. Understanding and targeting cancer stem cells: therapeutic implications and challenges , 2013, Acta Pharmacologica Sinica.
[140] I. Weissman,et al. Abstract 5218: Development of Anti-CD47 therapy for pediatric brain tumors. , 2013 .
[141] L. Esserman,et al. Abstract 3728: Anti-Notch1 antibody (OMP-52M51) impedes tumor growth and cancer stem cell frequency (CSC) in a chemo-refractory breast cancer xenograft model with an activating Notch1 mutation and screening for activated Notch1 across multiple solid tumor types. , 2013 .
[142] A. Stojadinovic,et al. Colorectal Cancer Biomarkers and the Potential Role of Cancer Stem Cells , 2013, Journal of Cancer.
[143] Rosanna La Rocca,et al. Human NK Cells Selective Targeting of Colon Cancer–Initiating Cells: A Role for Natural Cytotoxicity Receptors and MHC Class I Molecules , 2013, The Journal of Immunology.
[144] Y. Yoshioka,et al. Radiotherapy targeting cancer stem cells: current views and future perspectives. , 2013, Anticancer research.
[145] R. Abraham,et al. Long-term Tumor Regression Induced by an Antibody–Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells , 2012, Molecular Cancer Therapeutics.
[146] B. Czerniecki,et al. Dendritic cell-based vaccines: barriers and opportunities. , 2012, Future oncology.
[147] S. Kuo,et al. Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells. , 2012, Protein engineering, design & selection : PEDS.
[148] P. Kantoff,et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer , 2012, Cancer Immunology, Immunotherapy.
[149] M. Fischer,et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors , 2012, Proceedings of the National Academy of Sciences.
[150] S. Lyle,et al. Slow-cycling therapy-resistant cancer cells. , 2012, Stem cells and development.
[151] Sukhen C Ghosh,et al. CD44: a validated target for improved delivery of cancer therapeutics , 2012, Expert opinion on therapeutic targets.
[152] Aleksandar Sekulic,et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. , 2012, The New England journal of medicine.
[153] Yun-jie Wang,et al. Expression levels of Fas/Fas-L mRNA in human brain glioma stem cells. , 2012, Molecular medicine reports.
[154] A. Ferrando,et al. Preclinical Analysis of the γ-Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia , 2012, Molecular Cancer Therapeutics.
[155] I. Weissman,et al. The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. , 2012, Current opinion in immunology.
[156] A. Chang,et al. Cancer stem cell vaccination confers significant antitumor immunity. , 2012, Cancer research.
[157] Sean J Morrison,et al. Cancer stem cells: impact, heterogeneity, and uncertainty. , 2012, Cancer cell.
[158] S. Forman,et al. Stem-like Tumor-Initiating Cells Isolated from IL13Rα2 Expressing Gliomas Are Targeted and Killed by IL13-Zetakine–Redirected T Cells , 2012, Clinical Cancer Research.
[159] S. Okazaki,et al. Anti-Tumor Effect against Human Cancer Xenografts by a Fully Human Monoclonal Antibody to a Variant 8-Epitope of CD44R1 Expressed on Cancer Stem Cells , 2012, PloS one.
[160] C. Heeschen,et al. EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells , 2011, Clinical Cancer Research.
[161] R. Bhatia,et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. , 2011, Blood.
[162] J. Olson,et al. Cisplatin Restores TRAIL Apoptotic Pathway in Glioblastoma-Derived Stem Cells through Up-regulation of DR5 and Down-regulation of c-FLIP , 2011, Cancer investigation.
[163] Huan Yang,et al. Identification of CD44+CD24+ gastric cancer stem cells , 2011, Journal of Cancer Research and Clinical Oncology.
[164] J. Christensen,et al. Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab , 2011, Cell cycle.
[165] R. Majeti. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells , 2011, Oncogene.
[166] M. Weller,et al. APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. , 2011, Neuro-oncology.
[167] M. Peppelenbosch,et al. Hedgehog signaling maintains chemoresistance in myeloid leukemic cells , 2010, Oncogene.
[168] D. Silasi,et al. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. , 2010, American journal of obstetrics and gynecology.
[169] M. Friedrich,et al. Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T Cells , 2010, PloS one.
[170] H. Abken,et al. Can Engineered “Designer” T Cells Outsmart Chronic Hepatitis B? , 2010, Hepatitis research and treatment.
[171] W. McBride,et al. Radiation Resistance of Cancer Stem Cells: The 4 R's of Radiobiology Revisited , 2010, Stem cells.
[172] L. Yang,et al. Activation of the hedgehog-signaling pathway in human cancer and the clinical implications , 2010, Oncogene.
[173] J. Rich,et al. Hypoxia inducible factors in cancer stem cells , 2010, British Journal of Cancer.
[174] F. Pajonk,et al. Radiation responses of cancer stem cells , 2009, Journal of cellular biochemistry.
[175] J. Downing,et al. Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder. , 2009, Cancer cell.
[176] M. Konopleva,et al. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. , 2009, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[177] K. Black,et al. Antigen‐Specific T‐Cell Response from Dendritic Cell Vaccination Using Cancer Stem‐Like Cell‐Associated Antigens , 2009, Stem cells.
[178] Ash A. Alizadeh,et al. CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells , 2009, Cell.
[179] J. Dick,et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. , 2009, Cell stem cell.
[180] Patrick W. Lee,et al. Oncolytic reovirus effectively targets breast cancer stem cells. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[181] H. Fine,et al. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. , 2009, Cell stem cell.
[182] T. Wang,et al. Identification of Gastric Cancer Stem Cells Using the Cell Surface Marker CD44 , 2009, Stem cells.
[183] P. L. Poliani,et al. NK Cells Recognize and Kill Human Glioblastoma Cells with Stem Cell-Like Properties1 , 2009, The Journal of Immunology.
[184] Masahiro Inoue,et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.
[185] John M L Ebos,et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.
[186] Ling Xia,et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. , 2009, Cancer research.
[187] M. Poupon,et al. CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts , 2009, British Journal of Cancer.
[188] M. Dean. ABC Transporters, Drug Resistance, and Cancer Stem Cells , 2009, Journal of Mammary Gland Biology and Neoplasia.
[189] J. Lieberman,et al. let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells , 2007, Cell.
[190] Xin Wei Wang,et al. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. , 2007, Cancer research.
[191] H. Colman,et al. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. , 2007, Journal of the National Cancer Institute.
[192] I. Weissman,et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma , 2007, Proceedings of the National Academy of Sciences.
[193] Francisco Cervantes,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.
[194] Mark W. Dewhirst,et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.
[195] D. McDonald,et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. , 2006, The Journal of clinical investigation.
[196] J. Dick,et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells , 2006, Nature Medicine.
[197] S. Cole,et al. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1) , 2006, FEBS letters.
[198] N. Maitland,et al. Prospective identification of tumorigenic prostate cancer stem cells. , 2005, Cancer research.
[199] R. Henkelman,et al. Identification of human brain tumour initiating cells , 2004, Nature.
[200] D. Catovsky,et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.
[201] H. P. Deka Boruah,et al. Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells – An updated review , 2018, Experimental cell research.
[202] M. M. Elsherbini,et al. Oncolytic Viruses: A Gene Therapy for Treatment of Cancer in Companion Animals , 2018 .
[203] Depei Wu,et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. , 2018, American journal of cancer research.
[204] A. Chang,et al. Concise Reviews : Targeting Cancer Stem Cells Using Immunologic Approaches , 2015 .
[205] W. Murphy,et al. Advantages and clinical applications of natural killer cells in cancer immunotherapy , 2013, Cancer Immunology, Immunotherapy.
[206] Liwu Fu,et al. Targeting cancer stem cells: a new therapy to cure cancer patients. , 2012, American journal of cancer research.
[207] Pham Van Phuc,et al. Effects of Breast Cancer Stem Cell Extract Primed Dendritic Cell Transplantation on Breast Cancer Tumor Murine Models , 2011 .
[208] Alessandro Lugli,et al. Frequent EpCam protein expression in human carcinomas. , 2004, Human pathology.
[209] M. Slovak,et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. , 2003, Blood.
[210] T. Holyoake,et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. , 2002, Blood.